This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Bayer soluble guanylate cyclase (sGC) activator, BAY 1101042 (runcaciguat), is a once-daily (50 mg), oral clinical candidate in Ph. II…
molecule
2 years ago ●
1 min read
The Agios first-in-class oral MAT2A enzyme allosteric inhibitor, AG-270, is a Ph. I clinical candidate for tumors with MTAP gene loss. The inhibitor…
molecule
2 years ago ●
1 min read
The UC Berkeley and Novartis deubiquitinating enzyme-recruiting chimera (DUBTAC), NJH-2-057, has a warhead that covalently targets a non-catalytic allosteric cysteine on…
molecule
2 years ago ●
1 min read
The Roche GABAA-α5 selective negative allosteric modulator (NAM), basmisanil, is a Ph. II candidate for intellectual disability in Down syndrome. GABAA receptors…
molecule
2 years ago ●
1 min read
The Storm Therapeutics/Cambridge METTL3 RNA methyltransferase inhibitor, STM-2457, is a first-in-class catalytic inhibitor of the METTL3 RNA modifying enzyme. DNA-methyltransferase and…
molecule
2 years ago ●
1 min read
The AstraZeneca MAT2a allosteric inhibitor, compound 28, is a remarkably potent (25 nM in cells) in vivo tool compound generated from…
molecule
2 years ago ●
1 min read
Load More
